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Summary 
In the following paper we have presented the results of non-invasive and invasive prenatal diagnostic tests per-
formed on 2285 pregnant women from the Western-Pomeranian Region between 2005 and 2006. 
Material and methods: Retrospective analysis of screening tests on 2285 pregnant women.
Medical history, including age, weight, familial data pedigrees up to third degree relatives, accompanying diseases,
gestational complications in the family, type, dosage and period of any drugs intake, was obtained. Sonographic
screening and evaluation of maternal serum PAPP-A and βHCG levels.
Results: Screening tests identified 4.5% high-risk pregnancies in this group. 69% of the patients consented to inva-
sive diagnosis. As a result, genetic anomalies were detected in 43.7% of cases. Significant differences in βHCG 
levels correlated with oral gestagens intake and place of residence (coastal areas).
Conclusion: Broad use of certified non-invasive methods of prenatal screening allow substansial reduction of inva-
sive procedures with high levels of  positive prediction. Medical drugs intake as well as place of inhabitation may
influence on free βHCG levels.
Key words: prenatal diagnosis – analytic methods / biochemical markers / ultrasound /
/ pregnancy outcome /
Streszczenie 
Cel pracy: Celem pracy by∏o przeanalizowanie wyników nieinwazyjnych i inwazyjnych badaƒ prenatalnych
przeprowadzonych w regionie zachodniopomorskim w latach 2005-2006.
Materia∏ i metody: Analiza retrospektywna 2285 cià˝. Wywiad z uwzgl´dnieniem 3 pokoleniowego rodowodu,
badania ultrasonograficzne I trymestru wraz z testem podwójnym. Amniopunkcje ze standardowà ocenà kariotypu.
Wyniki: Drogà badaƒ przesiewowych wy∏oniono 4,5% cià˝ podwy˝szonego ryzyka, z których 69% podda∏o si´
amniopunkcji. Pozwoli∏o to na potwierdzenie w wysokim odsetku (43,7%) nieprawid∏owoÊci genetycznych. 
W badanej grupie ci´˝arnych zaobserwowano istotne zmiany w parametrach biochemicznych βHCG zale˝ne od
przyjmowanych leków (gestageny) oraz od miejsca zamieszkania (okolice nadmorskie).
Wnioski: Powszechne zastosowanie certyfikowanych nieiwazyjnych badaƒ prenatalnych pozwala na ograniczenie
liczby przeprowadzanych amniopunkcji przy utrzymaniu wysokiego wskaênika predykcji. Doustne przyjmowanie
niektórych leków oraz miejsce zamieszkania pacjentki mo˝e wp∏ywaç na poziomy wolnej podjednostki βHCG.
S∏owa kluczowe: diagnostyka prenatalna – analiza / ultrasonografia /
/ markery biochemiczne /
Correspondence to: 
Unit of Cytogenetics, Department of Pathology, Pomeranian Medical University, Szczecin, Poland
Po∏abska Street 4, 70-115 Szczecin
phone: +48 91 66 15 45, e-mail: kjp@onet.pl 
Otrzymano: 01.06.2008
Zaakceptowano do druku: 30.01.2009
Th
is 
c
p
 is
 fo
r p
er
so
na
l u
se
 on
ly 
- d
ist
rib
uti
on
 pr
oh
ibi
ted
.
 
 
 
 
 
 
 
-
 
 
 
 
 
 
 
Th
is
 c
op
y 
is 
fo
r p
er
so
na
l u
se
 o
nl
y 
- d
ist
rib
ut
io
n 
pr
oh
ib
ite
d.
   
   
 - 
   
   
Th
is 
co
py
 is
 fo
r p
er
so
na
l u
se
 o
nl
y 
- d
ist
rib
ut
io
n 
pr
oh
ib
ite
d.
   
   
 - 
   
   
Th
is 
co
py
 is
 fo
r p
er
so
na
l u
se
 o
nl
y 
- d
ist
rib
ut
io
n 
pr
oh
ib
ite
d.
   
   
 - 
   
   
Th
is 
co
py
 is
 fo
r p
er
so
na
l u
se
 o
nl
y 
- d
ist
rib
ut
io
n 
pr
oh
ib
ite
d.
   
   
 - 
   
   
Introduction
Standard prenatal screening protocol comprises NT, NB,
DV-flow, levels of maternal serum PAPPA and free βHCG
proteins evaluation [1, 2, 3, 4]. Values of these parameters are
influenced by individual features and, possibly, unique char-
acteristics of the patients [5, 6, 7, 8, 9].
In the following paper we have presented the results of pre-
natal screening tests performed between 2005-2006 in the
group of 2285 pregnant women from the Western Pomeranian
Region. 
Aim of the study
The aim of this study was to analyse the results of prena-
tal tests performed in our region between 2005 and 2006, as
well as to assess their validity. As a value of non-invasive tests,
we defined percentage of positive tests, which was confirmed
by amniocenthesis in low and high a priori risk groups. 
Material and Methods
In 2005 and 2006, non-invasive prenatal screening tests
were performed on 2285 women from the Western Pomeran-
ian Region in The Unit of Cytogenetics at The Department of
Genetics and Pathology, Pomeranian Medical University. The
study group consisted of 872 (38.2%) women, at least 35 years
of age (with primarily elevated risk, a priori), and 1413
(61.8%) younger pregnant women. Half of these women
wished to have the tests done, while others were referred to
them by their obstetricians. There was a small, statistically
insignificant, number of patients from the region who had
been tested in other centres.
Medical history, including age, weight, familial data pedi-
grees up to third degree relatives, accompanying diseases, ges-
tational complications in the family, type, dosage and period
of any drugs intake, was obtained. Retrospective analysis of
the place of residence was also performed. 
Sonographic screening was performed with Voluson730
PRO by 4 obstetricians – 2 of them certified by Foetal
Medicine Foundation (FMF). Simultaneously, maternal
serum PAPP-A and βHCG levels were evaluated. Biochemical
testing with the use of DPC reagents measured electrochemi-
luminescence. Medians of the examined parameters were
updated concurrently. The final risk assessment was done with
the use of PRISCA software. Cut-off risk value was assessed
at the level of 1:250.
Patients with elevated risk were given the chance of inva-
sive diagnosis. The presented analysis does not include the
results of invasive tests performed due to standard genetic
indications.
The results were statistically verified by t-Student test.
Results
The overall number of non-invasive tests amounted to
2285, both in the group of patients at the age of 35+, as well
as in the younger group (872 and 1413, respectively). Mean
age of the women was 33.3 years.
In the course of 2005 and 2006, there were 32311 labours,
including 2694 in the 35+ age group (8.34%) in the entire
Western Pomeranian Region. 
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Figure 1. The proportion of high and low risk in prenatal 
screening.
Figure 2. Results of invasive diagnosis.
Figure 3. Observed differences in biochemical results.Th
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Our analysis covered 7.07% of all pregnancies which
resulted in a delivery. Screening covered 32.37% and 4.8% of
women with primarily high and low-risk factors respectively.
Complex risk calculation revealed higher risk in 201
(8.8%) women, due to either maternal improper serum bio-
chemical results (in 189 cases – 8.3%) or sonographic features
(increased NT in 12 cases – 0.52%). Further sonographic eval-
uation of the subgroup with abnormal biochemical values
reduced their final individual risk in 98 women (52%). 
Invasive diagnosis was recommended to 103 (4.5% of all)
high-risk pregnant patients (complex risk calculation: age, NT,
maternal serum test): 61 cases ≥35y (7% of those ≥35y), and
42 cases <35y (3% of <35y). Amniocenthesis was performed
on 71 patients (69%): 48≥35y and 23<35y. Chromosomal
anomalies were found in 31 (43.7%) of all the examined cases
(15≥35y and 16 <35y). 
In case of 11 pregnant women, abnormal biochemical
serum test result was the only high-risk factor indicating the
need of invasive diagnosis. Out of these, chromosomal aber-
rations were confirmed in 9 cases (six trisomies 21, two tri-
somies 18 and one trisomy 13).
Although the results of the complex test revealed higher
risk in case of 32 women, they refused to consent to invasive
diagnosis (22 ≥35y and 10 <35y respectively). In this sub-
group, further diagnosis included sonographic evaluation in
the 20th  week of gestation. Markers for the most common tri-
somies were found in 14 cases. In this subgroup, 9 miscarriages
and 2 deaths of the foetus were observed, but were not fol-
lowed by any further genetic diagnosis. Among the rest, one
trisomy 21 and two  trisomies 18 have been identified postna-
tally. The remaining 18 newborns were free of any chromoso-
mal defects and were considered to be false positive results of
the complex non-invasive test.
The major factor resulting in final biochemical risk
enhancement proved to be high MoM values for βHCG,
observed especially in women who, following their obstetri-
cians’ recommendations, had been taking gestagens orally in
the early pregnancy. Retrospective analysis showed that 58
patients, suffering from the first trimester bleeding after assist-
ed fertilization or threatening miscarriage, were treated for
about 4 weeks with approximately 10 mg of dydrogesterone,
orally, twice a day, between 8th and 16th week of gestation. In
these patients, mean MoM value was statistically different
than in 964 controls and were 2.43 and 1,1 respectively. We
also observed statistically significant elevation of free βHCG
levels with mean MoM value of 3,83 in 30 patients who live in
direct vicinity of the sea (ÂwinoujÊcie, Mi´dzyzdroje, Mielno,
Dziwnów, Dar∏owo), when compared to 964 controls without
any gestagens treatment, living in other regions. (Table I).
Out of all biochemical screening tests performed, only
three were false negative. In one case a child with a simple tri-
somy 21 was born, the other two were translocation trisomies,
and were found by invasive diagnosis – amniocenthesis – per-
formed due to improper foetal sonographic features only. 
Discussion
Non-invasive screening test are performed to distinguish
pregnancies with an age-independent higher risk of three most
common chromosomal defects. In our centre, we have
observed a significantly reduced number of invasive diagnos-
tic procedures in women with age-associated elevated risk. 
Among 872 women from the 35+ age group, i.e. with ele-
vated risk a priori, the final high risk was calculated in case of
61 patients (7%) only. Out of them, only 48 decided to have
invasive diagnosis, and in 15 cases (31%) chromosomal defects
were found. In case of the remaining 811 women, with
reduced calculated risk, only 1 had a false negative result and,
consequently, a child with the Down syndrome was born.
In 1413 younger women with primarily low-risk, tests
revealed 41 pregnancies with higher final risk, which accounts
for 2.9% of all primarily low-risk pregnancies. Invasive diag-
nosis was performed in case of 35 patients and a chromosomal
defect was found in 16 cases (45.7%). Among the rest of 1372
women, in 2 cases with negative biochemical test results the
amniocenthesis was performed solely due to improper foetal
sonographic features. The 3 false negative results demonstrate
real sensitivity of complex screening tests at the level of 93.9%
with revealed of about 90% [1, 2, 10, 11].
In the group of 2285 examined women, 201 (8.8%) with
elevated risk were identified. The results of maternal serum
biochemical test, particularly high βCHG levels, increase the
final risk more often than high NT values. However, in 98
cases with improper biochemical values due to sonographic
evaluation and particularly low NT values, primarily high risk
was reduced to low, which emphasizes the importance of
proper sonographic evaluation [3, 12, 13]. 
The importance of simultaneous maternal serum bio-
chemical test is obvious, as 11 high-risk pregnancies were iden-
tified by theses tests alone, and in 9 of them trisomy was diag-
nosed. These observations prove once again that relying sole-
ly on NT values is not recommended as it is a less reliable and
sensitive test [1, 2, 12, 14].
In our centre, where strong emphasis was laid on proper
NT level check as well as on FMF audit’s, we have reached
high level of sensitivity: around 93.9% and 1.8% rate of false
positive results. It allows elimination of 52% of potential can-
didates for invasive techniques in women with primarily ele-
vated biochemical risk and reduction to only 4.5% of all
examined women, which corresponds with high effectiveness.
Positive prediction rate was around 43.7% and negative pre-
diction rate reached 99.9%. Half of the performed amniocen-
thesis procedures identified a defect in the foetus. Sieroszew-
ski estimates the positive prediction rate at the level of 21.2%.
However, in his analysis the major emphasis was placed on the
second trimester evaluation tests, which are commonly con-
sidered to be less sensitive [15]. 
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Table I. Levels of βHCG in studied groups.
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Other centres in Poland present even lower values, which
may result from the fact that it is easier to reach repeatable val-
ues in biochemical tests than sonographic ones [16]. Neverthe-
less, the tendency to reduce the total amount of amniocenthe-
sis is observed worldwide [17, 18, 19].
The influence of many different conditions on both,
maternal serum markers levels and MoM corrections in cal-
culation programs has been reported repeatedly. βHCG level
depends on weight, ethnicity and diet. Furthermore, smokers
have these levels significantly lower than non-smokers [5, 6, 7,
8]. We believe oral intake of gestagens was the major factor
elevating the levels of βHCG, contrary to the unaffected levels
of PAPPA. This problem should be investigated in the future
in more detail. Levels of βHCG in studied groups compared
to controls were significantly higher.
Elevated levels of βHCG in women treated with dydroges-
terone have not yet been described. The mechanism of this
influence remains unknown. It is possible that trophoblast
cells are not the only ones responsible for the βHCG produc-
tion, but that mononuclear cells (MNC) of the immune sys-
tem may secrete significant amounts of this protein. It is well
known the βHCG from MNCs stimulates the production of
progesterone, which is essential in the early stages of a preg-
nancy, and possibly the other way round. The mechanisms of
this process are described in detail only for the early develop-
ment of the embryo [6, 20, 21, 22]. 
Numerous research and data analysis were performed on
large population and they showed  various differences in
βHCG levels, which proved to be significantly lower in Asians
and Africans, when compared to Caucasians. Therefore, these
corrections are taken into consideration in many calculation
programmes. Levels of βHCG proved to be slightly lower in
the Hispanic population as well. However, no such compara-
tive analysis had been performed among smaller subpopula-
tions [5,23]. Undoubtedly, these corrections are crucial for the
assessment of the real risk, since overestimated MoM levels
are the major cause of false positive results. According to our
results, similarly to large populations, there might also be dif-
ferences among subpopulations. It is possible that one of the
reasons of βHCG growth in small subpopulations are physio-
logical processes of thyroid development, accompanied by
high iodine concentrations in coastal areas [23, 24].
About 7.07% of all pregnant women in the region were
included in our screening tests programme. Mean frequency of
the Down syndrome at the level of 1 in 650 newborns suggests
that statistically, among those who were not offered a chance
to undergo testing, at least 46 pregnancies with this chromo-
somal abnormality must have occurred, and about 44 of these,
thanks to the sensitivity of the screening, might have been dis-
covered prenatally.
At the end of this paper one should ask, whether it is
worth performing non-invasive diagnosis in patients with pri-
marily elevated risk. In some countries the high-risk age was
increased to 37 years [2, 25, 26]. 
Complex Screening Tests, as proposed by Nicholaides, ful-
fil all criteria of effective identification of the most common
anomalies with FPR at 5%. This system is based on the com-
plete elimination of age-related primary risk. Instead, it
replaces it with individual calculation of the risk, referring to
sonographic and biochemical parameters only [2, 3]. This
solution should be applied to all pregnant women. 
Economic factors, together with high costs and limitations
of invasive diagnosis, play an important role in the choice of
appropriate procedures, and stimulate the search for, relative-
ly cheaper, non-invasive diagnosis [25, 26, 27].
We have presented a way of reducing the necessity of inva-
sive diagnosis with low ratio of false negative results. Financial
means, otherwise used for unnecessary amniocenthesis, might
be spent on the popularization of the non-invasive systems,
provided that the criteria of high quality standards (highly
trained crew, accredited staff and frequent audits which main-
tain repeatability of the results) are fulfilled. 
Therefore, although we have reached satisfactory results of
the non-invasive tests, since 2007 we have been using only
FMF software and DelfiaXpress – accredited by the FMF
system – since neither the method nor DPC reagents have
gained accreditation.
Conclusions
1. In our centre, broad employment of non-invasive prenatal
screening allowed the reduction of the amniocenthesis rate
with stable level of positive prediction rate.
2. Oral gestagens intake and place of residence may influence
free βHCG levels in the first trimester screening.
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prof. dr hab. n. med. Jacek Bràzert
20-21.03.2009 Praktyczny kurs kolposkopii – certyfikat PTPZ HPV
Kierownictwo naukowe: 
prof. dr hab. n. med. Marek Sikorski
02.04.2009 Echokardiografia p∏odowa – warsztaty
Kierownictwo naukowe: 
prof. dr hab. n. med. M. Respondek-Liberska
03-04.04.2009 Echokardiografia p∏odu – kurs dla zaawansowanych
Kierownictwo naukowe: 
prof. dr hab. n. med. M. Respondek-Liberska
08-09.05.2009 Niep∏odnoÊç – diagnostyka i leczenie w prywatnej
praktyce lekarskiej
Kierownictwo naukowe: 
prof. dr hab. n. med. Jerzy Radwan
26-28.06.2009 Echokardiografia p∏odowa – kurs do dyplomu
skriningowego badania serca p∏odu
Kierownictwo naukowe: 
prof. dr hab. n. med. M. Respondek-Liberska
02.07.2009 Diagnostyka dopplerowska w po∏o˝nictwie 
z diagnostykà wad p∏odu – warsztaty
Kierownictwo naukowe: 
prof. dr hab. n. med. Jacek Bràzert, 
doc. dr hab. n. med. Marek Pietryga
03-05.07.2009 Diagnostyka wad wrodzonych i ultrasonografia 
w ginekologii
Kierownictwo naukowe: 
prof. dr hab. n. med. Jacek Bràzert
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
Mazowiecka Szko∏a Ultrasonografii
ul. Kwiatka 39/1, 09-410 P∏ock
tel./fax 024 367 36 16, kom. +48 601 345 372
Zapisy na kursy: +48 602 122 513
e-mail: mazowiecka@mszu.pl
www.mszu.pl
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